Programs under monitoring
MaxArc Global Health Impact Platform
Program Performance & Results Accountability
From targets to verified results — with evidence, not assertions.
A polished program-performance and results-accountability view: targets versus actuals, data quality, verification status, underperformance drivers, corrective actions, milestones, and outcomes across grants, countries, facilities, and diseases. Unverified or incomplete results are never presented as final. AI flags anomalies and reconciles records; authorized humans certify, decide, and close.
Total tracked indicators
Within 5% of target
More than 5% below
Escalation candidates
Past reporting due date
Completeness < 100%
Below quality threshold
Not yet verified
Not presented as final
Open / in progress
Past due date
Milestones completed
Results with evidence
Human decision required
Target vs actual results
Every result identifies its indicator, reporting period, responsible entity, data source, and evidence. Percentage indicators carry numerator/denominator provenance. Unverified results are marked "not final".
| Indicator | Target | Actual | Variance | Verification | Evidence / flags |
|---|---|---|---|---|---|
| Nets distributed to targeted households 2026 Q2 · Partner Alpha (synthetic) · District Referral Hospital (synthetic) |
20,000 | 19,100 num/den: — |
-4.5% | verified | evidence |
| Suspected malaria cases tested 2026 Q2 · Partner Alpha (synthetic) · Riverside Health Center (synthetic) |
95 | 71 num/den: 7,100/10,000 |
-25.3% | verified | evidence |
| PLHIV on ART 2026 Q2 · Partner Beta (synthetic) · District Referral Hospital (synthetic) |
15,000 | 14,200 num/den: — |
-5.3% | verified | evidence |
| Viral load suppression 2026 Q2 · Partner Beta (synthetic) · District Referral Hospital (synthetic) |
90 | 92 num/den: 4,600/5,000 |
+2.2% | verified | evidence |
| TB treatment success rate 2026 Q2 · Partner Beta (synthetic) · Hilltop Community Clinic (synthetic) |
88 | 74 num/den: 740/1,000 |
-15.9% | unverified not final | no evidence |
| TB cases notified 2026 Q2 · Partner Beta (synthetic) · Hilltop Community Clinic (synthetic) |
1,200 | 1,980 num/den: — |
+65% | disputed not final | no evidence improbable increase possible duplicate reporting |
Data quality
Data-quality issues are surfaced, never silently corrected.
| Result | Complete | Timeliness | Score | Status |
|---|---|---|---|---|
| RES-MAL-01-Q2 | 100% | on-time | 96 | acceptable |
| RES-MAL-02-Q2 | 100% | on-time | 90 | acceptable |
| RES-TB-01-Q2 | 80% | late | 62 | exception missing evidence and late submission |
| RES-TB-02-Q2 | 70% | on-time | 48 | exception improbable value; denominator not provided |
Underperformance
Attributable, classified, and escalated where required.
| Indicator | Severity | Variance | Root cause | Escalation |
|---|---|---|---|---|
| Suspected malaria cases tested | severe | -25.3% | commodity-stockout supply-driven · IP-ALPHA / FAC-RIVER |
escalated human review |
| TB treatment success rate | moderate | -15.9% | loss-to-follow-up service-delivery · IP-BETA / FAC-HILL |
open human review |
| PLHIV on ART | minor | -5.3% | seasonal demand-driven · IP-BETA / FAC-DIST |
monitor |
Corrective actions
- Emergency RDT resupply and stock-monitoring at FAC-RIVER — owner program-manager, due 2026-08-15, in-progress
- Community follow-up and treatment adherence support at FAC-HILL — owner program-manager, due 2026-06-30, overdue no evidence
- Obtain source documents for disputed TB notification figure — owner me-officer, due 2026-07-20, open no evidence
Milestones
- Mass net campaign completed (Malaria Program) — target 2026-06-30 completed
- Differentiated ART service scale-up (HIV Program) — target 2026-09-30 on-track
- TB active case-finding expansion (TB Program) — target 2026-06-30 delayed
Outcome & impact
- Confirmed malaria incidence per 1000 — baseline 210, current 176, target 150 improvingdeclining incidence trend, below-target pace
- Viral load suppression among ART patients (%) — baseline 78, current 92, target 90 improvingtarget achieved
- TB treatment success rate (%) — baseline 82, current 74, target 88 worseningregression requires corrective action
Variance distribution
- on or above 2
- 0 to 10 below 2
- 10 to 20 below 1
- over 20 below 1
Anti-fabrication & anti-manipulation signals (AI-assisted, human-decided)
- improbable increase (RES-TB-02-Q2) — TB notifications 65% above target with no denominator and disputed verification; possible fabrication or duplicate reporting Next: authorized reviewer obtains source documents before any reporting. human decision required
- unverified result (RES-TB-01-Q2) — TB treatment success reported without evidence and marked not final Next: verify against source register; do not present as final. human decision required
- severe underperformance (RES-MAL-02-Q2) — Testing coverage 25% below target driven by RDT stockout Next: link to stockpile-logistics stockout; track corrective action. human decision required
- denominator manipulation watch — Watch for percentage indicators reported without numerator/denominator provenance Next: require numerator/denominator for all percentage indicators. human decision required
AI posture
AI assists with
- detect anomalous indicator movements
- identify duplicate or inconsistent reporting
- flag improbable numerator/denominator patterns
- detect missing or late submissions
- compare target, baseline, and result consistency
- surface underperformance drivers
- prioritize corrective-action review
- reconcile grant, facility, partner, and program records
- summarize trends for authorized reviewers
- support data-quality triage
AI must never
- autonomously certify results
- autonomously change targets, baselines, or reported values
- autonomously close corrective actions
- autonomously approve milestone changes
- autonomously suppress underperformance
- autonomously publish unverified results
- bypass human authorization, evidence, or audit controls
AI supports program-performance accountability: it detects anomalous indicator movements, identifies duplicate or inconsistent reporting, flags improbable numerator/denominator patterns, detects missing or late submissions, compares target/baseline/result consistency, surfaces underperformance drivers, prioritizes corrective-action review, reconciles grant/facility/partner/program records, summarizes trends for authorized reviewers, and supports data-quality triage. AI never certifies results, changes targets/baselines/reported values, closes corrective actions, approves milestone changes, suppresses underperformance, publishes unverified results, or bypasses human authorization, evidence, or audit controls.
Runtime boundary & linkage
- Impact runtime:
impact.maxarchealth.comon127.0.0.1:3201. - Linked to fund accountability, stockpile & logistics, lab operations, patient continuity, and asset management without coupling to MaxTrax EHR.
- Medical Library boundary remains separate at
library.maxarchealth.com(port3101) and is not used here. - MaxTrax EHR remains separate; this is not a full EHR.
- Legacy routes
/programsand/performance-indicatorsremain available and unchanged. - This is an operational accountability dashboard, not an official reporting submission.